Possible andrologic markers in elevated neonatal 17-hydroxyprogesterone by Cavarzere P. et al.
2Paolo Cava
Monica Vi
Rossella G
Roberto Fr
Silvia Perl
Marta Cam
Francesca
Franco An
Luciano Ta
Pediatric C
Verona,
Received Jan
2010; publis
P.C. has noth
nothing to d
disclose. M
F.A. has no
Reprint reques
versity of V
Verona, Ita
yahoo.it).
Fertilit
Copyri
350Possible andrologic markers in elevated
neonatal 17-hydroxyprogesteroneIn this prospective study, we analyzed 30 male infants with increased neonatal 17-hydroxyprogesterone (17OH-P)
(patients) and for comparison 52 age-matched healthy babies (control subjects) with the aim of investigating the
hypothalamic-pituitary-testis axis in the first 6 months of life. Although T, FSH, and LH levels were not signifi-
cantly different in patients and control subjects, inhibin B was higher in patients than in control subjects. Therefore
we suggest a clinical follow-up of these babies during childhood and puberty to verify the evolution of their con-
dition. (Fertil Steril 2010;94:2350–2. 2010 by American Society for Reproductive Medicine.)
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axis is transiently activated in males, with increased gonadotro-
pins, testosterone, and inhibin B levels (1, 2). Peak levels are
observed at around the third month of life. Later on, serum
hormone levels significantly decrease, remaining low until
puberty (3–5).
Undetectable levels of inhibin B were observed in infants with
bilateral absent testis, and lower levels were seen in infants with
cryptorchidism, monorchidism, and testicular damage (4, 6, 7).
Recently, low levels of inhibin B were also described in
prepubertal boys with congenital adrenal hyperplasia (CAH),
even in the absence of testicular adrenal rest (8). Inhibin B levels
in males presenting neonatal increase of 17-hydroxyprogesterone
(17OH-P) (40% of all positives at neonatal screening for 21-hy-
droxylase deficiency [21-OHD] [9]) are presently unknown. This
information, however, is interesting in view of recent studies re-
porting a high rate of infertility in patients with congenital adrenal
disease (10–13). As a matter of fact, it is not known whether anrzere, M.D.
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Therefore, the aim of the present prospective study was to inves-
tigate the hypothalamic-pituitary-gonadal axis in the first 6 months
of life in male babies with increased neonatal 17OH-P values, and
to compare their data with those obtained in normal infants of the
same age.
Thirty newborns with neonatal hyper-17OHP-emia (patients)
were analyzed. Inclusion criteria were: male gender, gestational
age (GA) >36 weeks, uncomplicated gestation and delivery, birth
weight (BW) >2,500 g, absence of congenital disease, and in-
creased 17OH-P levels at neonatal screening for 21-OHD. Exclu-
sion criteria were: preterm delivery, classic salt wasting form of
21-OHD, and acute illness in the first days of life.
For comparison, we enrolled 52 age-matched healthy male
babies (control subjects), with the same inclusion and exclusion
criteria, except for displaying among the inclusion criteria values
of 17OH-P within the normal reference range.
The study was conducted in compliance with the terms of the
Helsinki II Declaration, and was approved by the Institutional Re-
view Board of Verona. Informed written consents were obtained
from the parents of the patients and control subjects.
The newborn screening 17OH-P cut-off level for term babies
was set at 40 nmol/L. Positive babies at screening were recalled
to confirm the result. For each patient, we recorded GA, BW, birth
length (BL), and state of health. These infants were assessed every
3 months from birth to 6 months of life and submitted to complete
physical examination. All of them underwent blood withdrawal to
measure serum 17OH-P, electrolytes, FSH, LH, T, and inhibin B
levels. Testicular volume was assessed using a standard Prader or-
chidometer. Testicular ultrasound scanning was performed at the
first and third evaluations by the same radiologist.
For comparison, we assessed T, gonadotropins, and inhibin B in
control subjects at approximately the same age as the patients.
Newborn screening for 21-OHD is based on 17OH-P fluoroim-
munoassay on blood spots (AutoDelfia Neonatal 17OH-P Kit;
Wallac Oy, Turku, Finland). Serum FSH, LH, and T measurements
were determined by immunometric assay (Immulite 2000;0015-0282/$36.00
ublished by Elsevier Inc. doi:10.1016/j.fertnstert.2010.04.040
TABLE 1
Growth and hormonal data in patients and control
subjects (mean ± SD).
Patients
(n[30)
Control subjects
(n[52)
Birth
Weight (g) 3,251.5  362.0 3,141.4  460.3
Length (cm) 50.3  1.8 50.6  2.0
GA (wk) 38.7  1.3 39.1  1.2
Screening 17OH-P
(nmol/L)
133.5  228.2y 11.1  5.4
First month
Weight (g) 3,857.2  574.1 3,886.8  550.6
Length (cm) 53.1  2.1 53.6  2.1
FSH (U/L) 1.4  1.0 1.4  1.6
LH (U/L) 3.0  2.1 3.3  2.4
T (nmol/L) 8.2  7.2 4.5  5.0
Inhibin B (pg/mL) 119.9  50.6* 89.5  37.4
Age (d) 25.7  9.2 25.2  11.7
Third month
Weight (g) 6,063.4  673.7* 5,076.0  711.7
Length (cm) 60.6  1.7y 56.3  3.0
FSH (U/L) 1.6  0.8 2.0  1.3
LH (U/L) 3.0  2.3 2.8  1.9
T (nmol/L) 5.8  3.1 2.7  2.9
Inhibin B (pg/mL) 183.1  87.8z 141.7  40.0k
Age (d) 90.0  13.2 86.6  26.7
Sixth month
Weight (g) 7,742.5  746.2* 6,981.9  1,268.7
Length (cm) 67.0  1.5 65.4  3.8
FSH (U/L) 0.8  0.5 1.0  1.3
LH (U/L) 0.8  0.6 1.2  1.3
T (nmol/L) 1.0  1.0 0.1  0.1
Inhibin B (pg/mL) 202.2  78.7*,x 117.4  69.1
Age (d) 180.8  6.6 180.7  20.9
Note: 17OH-P ¼ 17-hydroxyprogesterone; GA ¼ gestational age.
* Patients vs. control subjects: P< .05.
y Patients vs. control subjects: P< .001.
z Patients, first month vs. third month: P< .005.
x Patients, first month vs. sixth month: P< .001.
k Control subjects, first month vs. third month: P< .001.
Cavarzere. Correspondence. Fertil Steril 2010.
FSiemens, Erlangen, Germany). Serum 17OH-P was assayed by
RIA (DSL-5000 Active 17a-OH Progesterone Coated-Tube
Radioimmunoassay; Diasorin, Saluggia, Italy), and serum inhibin
B by ELISA (Active Inhibin B ELISA, Diagnostic Systems
Laboratories, Webster, TX).
Statistical analyses were performed using SPSS 16.0 for Win-
dows (SPSS, Chicago, IL). Comparisons between groups were per-
formed by using Student t test or Mann-Whitney U test, and
correlations by using Spearman or Pearson test, whenever
appropriate.
No differences in patients’ and control subjects’ neonatal fea-
tures were detected; however, during the clinical follow-up, pa-
tients showed a significant increased growth (Table 1). All
patients’ testicular volumes appeared normal for age, and they re-
mained in the normal range for age during the entire follow-up. No
differences were reported in their testis size compared with control
subjects. Testicular ultrasound showed, in all of the subjects, both
testes in the scrotum. None presented adrenal rest or alterations in
testicular parenchyma. Hydrocele was found in 10 babies at first
examination, bilateral in five of them and persistent in one.
All patients showed normal electrolyte values but increased
17OH-P serum levels at the first measurement (median 17OH-P:
37.5 [range 12.6–210.0] nmol/L). Then, 17OH-P levels decreased
with age (median 10.1 [5.4–30.0] nmol/L and 2.7 [1.4–36.0] nmol/L
at 3 and 6 months, respectively), reaching the reference range at
the sixth month of life (14, 15). None of them needed treatment
for hyper-17OHP-emia.
Whereas inhibin B was higher in patients than in control sub-
jects, no significant differences in testosterone and gonadotropins
levels were found (Table 1).
In the patients, we did not find any significant correlation be-
tween inhibin B, FSH, and T in the first period of life. Correlations
were found between inhibin B and LH at the first serum evaluation
(r ¼ 0.447; P<.05) and between screening 17OH-P levels and in-
hibin B levels at the first month of life (r ¼ 0.617; P<.005). The
decrease of 17OH-P levels between the first and the third evalua-
tions correlated with the increase in weight between the third and
the sixth month (r ¼ 0.600; P<.05). In the control subjects, no
correlations were observed.
None of the patients presented conditions explaining their in-
creased 17OH-P. No severe enzymatic deficiencies were evident
at birth, and their androgen pattern allowed us to exclude a simple
virilizing form of CAH, although we could not exclude a nonclas-
sic form of the disease (9). Consequently, we hypothesized that the
neonatal hyper-17OHP-emia was probably due to a slow enzy-
matic maturation in the adrenal steroidogenesis process.
In agreement with earlier studies (2, 5, 16), we did not find any
correlation between FSH and inhibin B in the first months of life,
whereas patients’ LH and inhibin B, at the first serum evaluation,
were positively correlated. These data seem to confirm the
hypothesis of a role played by LH in the initial regulation of
inhibin B synthesis and secretion (16, 17).
There is no evidence that increased 17OH-P levels in the first
year of life modify fertility in later years, and data of inhibin B
levels in newborns with congenital adrenal disease are lacking.
Nevertheless, some studies described a higher risk of infertilityertility and Sterilityin adult males with CAH, considering inhibin B to be an important
index of fertility as a marker of Sertoli cell function (10–13, 18).
Inhibin B was demonstrated to be a marker of Sertoli cells
during childhood as well (2–4), and it was hypothesized that it
might be a predictor of future fertility in male newborns (19). Re-
cently, low inhibin B levels were described in prepubertal boys
with CAH, suggesting a gonadal dysfunction in these patients,
although the impact of this finding on future fertility remained
unknown (8). In contrast, our most intriguing finding was the
increased levels of inhibin B in infants with elevated neonatal
17OH-P values compared with control subjects.
High inhibin B levels were described in prepubertal patients
with specific disorders in the androgens’ biosynthesis or action.
The cause of this finding is still unknown, but it was hypothesized
that the deficit of testosterone action was the primus movens, fol-
lowed by an increased daily production of FSH and/or its insuffi-
cient paracrine action on Sertoli cells (20, 21). Another speculative2351
2interpretation of our data could involve Sertoli cells, which in case
of androgens’ excess might be stimulated by elevated neonatal
17OH-P levels, and consequently display a precocious
maturation with active proliferation and increased production of
inhibin B (22, 23). This hypothesis is indirectly confirmed by
the correlation between screening 17OH-P values and inhibin B
levels. However, the role of neonatal hyper-17OHP-emia in the
possible precocious maturation of Sertoli cells and their relation-
ship on future fertility remain unclear.
Infants with neonatal hyper-17OHP-emia had heavier weight
and longer length than control subjects at 3 months of life, and
this finding was confirmed at the sixth-month evaluation only for
weight.
An earlier study described no differences in the growth during
the first year of life in children affected by CAH undiagnosed at
birth, suggesting the presence of relative resistance to androgen
excess during this period (24). This finding was supported by the
evidence of normal growth in other pathologic conditions with352 Cavarzere et al. Correspondenceelevated androgen levels (25). In contrast, some studies analyzed
the effect in the uterus of androgen excess, reporting that BL of
babies with CAH was higher than that of the normal population
(26, 27). In the present patients, BW and BL were not
significantly different compared with control subjects, but, over
time, their weight and length exceeded those of the control
subjects. Therefore, we can hypothesize that neonatal hyper-
17OHP-emia influences the growth for some months after birth.
The correlation between postnatal decrease of 17OH-P levels
and the increase of weight between the third and the sixth months
indirectly confirm this hypothesis.
In conclusion, we found that male infants with elevated neonatal
17OH-P values had higher inhibin B levels and increased weight
compared with a control population until at least 6 months of
life. Whether elevated inhibin B levels in the first months of life
have an effect on testicular function later in life remains unknown.
Further follow-up of these babies during childhood and puberty is
useful to assess the evolution of their clinical condition.REFERENCES1. Winter JS, Hughes IA, Reyes FI, Faiman C.
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